Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.04
MNK's Cash-to-Debt is ranked lower than
95% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. MNK: 0.04 )
Ranked among companies with meaningful Cash-to-Debt only.
MNK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.04  Med: 0.18 Max: N/A
Current: 0.04
Equity-to-Asset 0.35
MNK's Equity-to-Asset is ranked lower than
86% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. MNK: 0.35 )
Ranked among companies with meaningful Equity-to-Asset only.
MNK' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.25  Med: 0.34 Max: 0.41
Current: 0.35
0.25
0.41
Interest Coverage 0.42
MNK's Interest Coverage is ranked lower than
98% of the 635 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 105.95 vs. MNK: 0.42 )
Ranked among companies with meaningful Interest Coverage only.
MNK' s Interest Coverage Range Over the Past 10 Years
Min: 0.42  Med: 2.69 Max: 470.4
Current: 0.42
0.42
470.4
Piotroski F-Score: 5
Altman Z-Score: 0.61
Beneish M-Score: -2.59
WACC vs ROIC
12.58%
-1.52%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 4.92
MNK's Operating Margin % is ranked lower than
54% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. MNK: 4.92 )
Ranked among companies with meaningful Operating Margin % only.
MNK' s Operating Margin % Range Over the Past 10 Years
Min: 2.63  Med: 11.68 Max: 18.26
Current: 4.92
2.63
18.26
Net Margin % 17.57
MNK's Net Margin % is ranked higher than
59% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. MNK: 17.57 )
Ranked among companies with meaningful Net Margin % only.
MNK' s Net Margin % Range Over the Past 10 Years
Min: -19.35  Med: 7 Max: 19.04
Current: 17.57
-19.35
19.04
ROE % 10.91
MNK's ROE % is ranked lower than
54% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. MNK: 10.91 )
Ranked among companies with meaningful ROE % only.
MNK' s ROE % Range Over the Past 10 Years
Min: -10.28  Med: 7.85 Max: 12.17
Current: 10.91
-10.28
12.17
ROA % 3.63
MNK's ROA % is ranked lower than
61% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. MNK: 3.63 )
Ranked among companies with meaningful ROA % only.
MNK' s ROA % Range Over the Past 10 Years
Min: -3.91  Med: 2.77 Max: 4.04
Current: 3.63
-3.91
4.04
ROC (Joel Greenblatt) % 12.47
MNK's ROC (Joel Greenblatt) % is ranked higher than
59% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. MNK: 12.47 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MNK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 3.34  Med: 18.27 Max: 50.3
Current: 12.47
3.34
50.3
3-Year Revenue Growth Rate 0.80
MNK's 3-Year Revenue Growth Rate is ranked lower than
68% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. MNK: 0.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MNK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -11.2  Med: -10.1 Max: 0.8
Current: 0.8
-11.2
0.8
3-Year EBITDA Growth Rate 51.90
MNK's 3-Year EBITDA Growth Rate is ranked higher than
90% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. MNK: 51.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MNK' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -7.5  Med: 11.5 Max: 51.9
Current: 51.9
-7.5
51.9
GuruFocus has detected 2 Warning Signs with Mallinckrodt PLC $MNK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MNK's 30-Y Financials

Financials (Next Earnings Date: 2017-08-08 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

MNK Guru Trades in Q2 2016

Steven Cohen 120,400 sh (New)
David Dreman 4,448 sh (+10.45%)
First Eagle Investment 187 sh (unchged)
Mario Gabelli 14,562 sh (unchged)
John Paulson 8,371,080 sh (-6.46%)
Ken Heebner 1,014,000 sh (-9.87%)
Paul Tudor Jones 5,434 sh (-28.71%)
Joel Greenblatt 246,825 sh (-57.51%)
» More
Q3 2016

MNK Guru Trades in Q3 2016

Jim Simons 207,102 sh (New)
Paul Tudor Jones 7,336 sh (+35.00%)
Joel Greenblatt 327,572 sh (+32.71%)
First Eagle Investment 187 sh (unchged)
David Dreman 4,448 sh (unchged)
Steven Cohen Sold Out
Mario Gabelli 14,462 sh (-0.69%)
John Paulson 7,974,472 sh (-4.74%)
Ken Heebner 880,500 sh (-13.17%)
» More
Q4 2016

MNK Guru Trades in Q4 2016

Steven Cohen 120,900 sh (New)
Paul Tudor Jones 19,556 sh (+166.58%)
Mario Gabelli 17,425 sh (+20.49%)
John Paulson 7,976,872 sh (+0.03%)
First Eagle Investment 187 sh (unchged)
Jim Simons Sold Out
Joel Greenblatt Sold Out
Ken Heebner Sold Out
David Dreman 84 sh (-98.11%)
» More
Q1 2017

MNK Guru Trades in Q1 2017

HOTCHKIS & WILEY 818,140 sh (New)
Mario Gabelli 29,425 sh (+68.87%)
First Eagle Investment 187 sh (unchged)
David Dreman Sold Out
John Paulson 7,500,972 sh (-5.97%)
Steven Cohen 98,100 sh (-18.86%)
Paul Tudor Jones 9,234 sh (-52.78%)
» More
» Details

Insider Trades

Latest Guru Trades with MNK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:AKRX, NYSE:CTLT, NAS:OPK, OTCPK:STDAF, NYSE:TARO, NYSE:VRX, NYSE:PTHN, NAS:MDCO, OTCPK:HYPMY, OTCPK:HKMPY, NAS:ENDP, NAS:IRWD, OTCPK:SWPIF, NAS:PCRX, OTCPK:EVTCY, NAS:HZNP, NAS:SUPN, NAS:RDUS, NYSE:RDY, NAS:PAHC » details
Traded in other countries:MCD.Germany,
Headquarter Location:UK
Mallinckrodt PLC along with its subsidiaries operates in a specialty biopharmaceutical business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products.

Mallinckrodt is a specialty pharmaceutical company that was spun off from Covidien. The company has two segments in branded pharmaceuticals and generic drugs following the sale of its nuclear imaging business in 2016. Branded drugs make up approximately 70% of revenue. The firm's generic drug segment focuses primarily on products in the pain therapeutic area.

Top Ranked Articles about Mallinckrodt PLC

MNK DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Mallinckrodt plc and a Lead Plaintiff Deadline of March 27, 2017

NEW YORK, March 24, 2017 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Columbia on behalf of investors who purchased Mallinckrodt plc (:MNK) securities between July 14, 2014, and January 18, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/mallinckrodt-plc. There is no cost or obligation to you. According to the complaint, throughout the Class Period, Mallinckrodt and its acting President and Chief Executive Officer, Mark Trudeau, misrepresented the efficacy of Mallinckrodt’s business model and its ability to maintain sustainable revenue. Specifically, the complaint alleges that Defendants made false and/or misleading statements and/or failed to disclose that Mallinckrodt engaged in unlawful anticompetitive practices to maintain H.P. Acthar Gel’s (“Acthar”) monopoly status as the only FDA-approved therapeutic preparation of adrenocorticotropic hormone and that Mallinckrodt’s increasing reliance on Medicare and Medicaid meant that the Company’s monopolistic Acthar revenue would be threatened if the government took action to limit the price paid for the drug by taxpayers. If you suffered a loss in Mallinckrodt you have until March 27, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/mallinckrodt-plc. Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights.  Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]

Read more...
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Mallinckrodt Public Limited Company (MNK) & Lead Plaintiff Deadline: March 27, 2017

NEW YORK, March 23, 2017 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Mallinckrodt Public Limited Company (“Mallinckrodt” or the “Company”) (:MNK) and certain of its officers, on behalf of shareholders who purchased Mallinckrodt securities between November 25, 2014 and January 18, 2017 inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: http://www.bgandg.com/mnk.   This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934. The Complaint alleges that throughout the Class Period, Defendants made false and misleading statements and failed to disclose material adverse facts regarding sustainability of the Company’s monopolistic HP Acthar Gel (“Acthar”) profits and the exposure of Acthar to reimbursement rates by Medicare and Medicaid. Furthermore, Defendants made false and/or misleading statements and/or failed to disclose that Acthar’s monopoly position as the only FDA-approved adrenocorticotropic hormone preparation was the result of illicit anticompetitive measures and did not reveal that its growing reliance on Medicare and Medicaid meant that Mallinckrodt’s monopolistic Acthar revenue would be threatened if the government pursued action to limit the price paid for this drug by taxpayers. Once this news was made public, Mallinckrodt stock dropped, damaging investors. On November 16, 2016, Citron Research published an article called “Mallinckrodt CEO FRAUD exposed by the new Medicare Drug Dashboard." The article accuses Mallinckrodt’s CEO, Mark C. Trudeau, of lying to stockholders on a conference call on October 5, 2015. Turdeau said that the Company’s total Medicare and Medicaid spending on Acthar is “a little bit higher than” 25% of Acthar’s sales. Citron Research then revealed the Centers for Medicare & Medicaid Services’s data that showed Medicare and Medicaid spending on Acthar in 2015 that was roughly 61% of Acthar’s sales. Following this news, Mallinckrodt stock dropped $8.15 per share or about 12% to close at $59.65 per share on November 16, 2016. Later, on January 18, 2017, the Federal Trade Commission revealed that Mallinckrodt had agreed to pay $100 million in settlement fees following an investigation against its anticompetitive and unlawful efforts to prevent an alternative ACTH treatment from reaching the U.S. market. A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/mnk  or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Mallinckrodt you have until March 27, 2017 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]

Read more...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mallinckrodt plc of Class Action Lawsuit and Upcoming Deadline – MNK

NEW YORK, March 20, 2017 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Mallinckrodt plc (“Mallinckrodt” or the “Company”) (:MNK) and certain of its officers.  The class action, filed in United States District Court, District of Columbia, is on behalf of a class consisting of investors who purchased or otherwise acquired Mallinckrodt securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934. If you are a shareholder who purchased Mallinckrodt securities between November 25, 2014 and January 18, 2017, both dates inclusive, you have until March 27, 2017 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.  To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.  [Click here to join this class action] Mallinckrodt is a public limited company organized in Ireland with its U.S. headquarters in St. Louis, Missouri.  Mallinckrodt develops and produces specialty pharmaceutical products, including generic drugs and imaging agents, and has in excess of $3.3 billion in annual revenue. On August 14, 2014, Mallinckrodt acquired Questcor Pharmaceuticals, Inc. (“Questcor”) in a $5.6 billion transaction. As a result of the acquisition, Mallinckrodt added HP Acthar Gel (“Acthar”), an injectable medication made from pigs’ pituitary glands, to its drug portfolio. Acthar is the only approved therapeutic preparation of adrenocorticotropic hormone (“ACTH”) in the U.S., and is approved by the U.S. Food and Drug Administration (“FDA”) as a treatment for 19 different conditions, including infantile spasms, and difficult-to-treat autoimmune and inflammatory conditions. In June 2013, Questcor had acquired the U.S. rights to market a synthetic ACTH drug, Synacthen Depot (“Synacthen”) from Novartis International AG. Although not stated at the time, Questcor’s acquisition of Synacthen was for the purpose of preventing its competitors from obtaining FDA approval for an alternative ACTH treatment, thereby maintaining its U.S. monopoly on ACTH treatments. The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.  Specifically, Defendants made false and misleading statements and failed to disclose material adverse facts about the long-term sustainability of the Company's monopolistic Acthar Gel ("Acthar") revenues and the dependence of the Company’s Acthar revenues on reimbursement by Medicare and Medicaid. On November 16, 2016, Citron Research published a report (the “Citron Report”) accusing Mallinckrodt and its Chief Executive Officer, Mark Trudeau, of downplaying the Company’s reliance on Medicare and Medicaid for Acthar revenue.  According to the Citron Report, a review of information published by the Centers for Medicare and Medicaid Services indicated that Medicare and Medicaid payments collectively amounted to 61.32% of Mallinckrodt’s Acthar revenues in 2015.  Following the Citron Report, Mallinckrodt’s share price fell $8.15, or 12.02%, to close at $59.65 on November 16, 2016.  On November 29, 2016, during a conference call, Trudeau advised investors “Acthar now represents a significantly greater proportion of our operating income than one-third.”  On this news, Mallinckrodt’s share price fell $5.25, or 9.1%, to close at $52.42 on November 29, 2016.  On January 18, 2017, the Federal Trade Commission (“FTC”) announced that Mallinckrodt had agreed to pay $100 million in connection with a joint settlement with the FTC and several states concerning charges that the Company’s efforts to stifle competing ACTH drugs had violated U.S. antitrust laws.  On news of the settlement, Mallinckrodt’s share price fell $2.89, or 5.85%, to close at $46.53 on January 18, 2017. The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]

Read more...
UPDATE: Hagens Berman Alerts Mallinckrodt Investors to the Expanded Class Period and Reminds them of the March 27, 2017 Lead Plaintiff Deadline

SAN FRANCISCO, March 15, 2017 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP alerts investors in Mallinckrodt PLC (:MNK) to the expanded class period and reminds them of the March 27, 2017 Lead Plaintiff deadline.
If you purchased or otherwise acquired securities of MNK during the expanded class period -- between July 14, 2014 and January 18, 2017 and suffered over $50,000 in losses contact Hagens Berman Sobol Shapiro LLP.  For more information visit: https://www.hbsslaw.com/cases/MNK or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected]. Beginning in late 2014, MNK allegedly made assurances to investors that its drug, Acthar, produced sustainable revenues that were mostly attributable to sources other than Medicare and Medicaid. However, on November 16, 2016, a Citron Research report revealed that the percentage of Acthar 2014 and 2015 revenues attributable to Medicare alone was over 45% and 48%, respectively.  Citron also reported that the total percentage of Acthar 2014 and 2015 revenues attributable to both Medicare and Medicaid was over 60% and 61%, respectively.  This news drove the price of MNK shares down over 18%. In January 2017 the Company received a subpoena from the SEC for documents related to MNK’s public statements, filings and other disclosures regarding Acthar sales, profits, revenue, promotion and pricing. On January 18, 2017, the U.S. Federal Trade Commission announced that MNK would pay $100 million to settle charges that Acthar revenues were the product of an illegal monopoly.  This news drove the price of MNK down over 5%. “We’re evaluating management’s knowledge about revenue sources and omissions concerning when the FTC commenced its investigation into the unlawful practices and the subjects of the SEC’s inquiry,” said Hagens Berman partner Reed Kathrein. Whistleblowers: Persons with non-public information regarding MNK should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.  Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.  For more information, call Reed Kathrein at 510-725-3000 or email [email protected]. About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities.  The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com.  For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact:
Reed Kathrein, 510-725-3000

Read more...
MALLINCKRODT SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Mallinckrodt Public Limited Company - (MNK)

NEW ORLEANS, La., March 10, 2017 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., reminds investors that they have until March 27, 2017 to file lead plaintiff applications in a securities class action lawsuit against Mallinckrodt Public Limited Company (:MNK), if they purchased the Company’s securities between November 25, 2014 and January 18, 2017, inclusive (the “Class Period”).  The action is pending in United States District Court for the District of Columbia. 
What You May Do If you purchased securities of Mallinckrodt and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by March 27, 2017. About the Lawsuit The complaint alleges that, throughout the Class Period, Mallinckrodt and its CEO, Mark Trudeau, made a series of false and misleading statements and failed to disclose material adverse facts about the long-term sustainability of Mallinckrodt’s revenues for HP Acthar Gel (“Acthar”), the only FDA-approved adrenocorticotropic hormone preparation.  The action alleges that Acthar’s monopoly status was the product of unlawful anticompetitive practices and failed to disclose that its increasing reliance on Medicare and Medicaid meant that Mallinckrodt’s monopolistic Acthar revenue would be threatened if the government took action to limit the price paid for this drug by taxpayers. About Kahn Swick & Foti, LLC KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana. To learn more about KSF, you may visit www.ksfcounsel.com.
Contact:

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
206 Covington St.
Madisonville, LA 70447

Read more...
MNK ALERT: Rosen Law Firm Reminds Mallinckrodt Public Limited Company Investors of Important Deadline in Class Action – MNK

NEW YORK, March 10, 2017 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Mallinckrodt Public Limited Company securities (:MNK) from November 25, 2014 through January 18, 2017, inclusive (the “Class Period”) of the important March 27, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Mallinckrodt investors under the federal securities laws. To join the Mallinckrodt class action, go to http://rosenlegal.com/cases-1002.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. According to the lawsuit, throughout the Class Period Mallinckrodt and its Chief Executive Officer, Mark Trudeau, made a series of false and misleading statements and failed to disclose material adverse facts about the long-term sustainability of Mallinckrodt’s monopolistic HP Acthar Gel (“Acthar”) revenues and the exposure of Acthar to reimbursement rates by Medicare and Medicaid. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that Acthar’s monopoly status as the only FDA-approved adrenocorticotropic hormone preparation was the product of unlawful anticompetitive practices and failed to disclose that its increasing reliance on Medicare and Medicaid meant that Mallinckrodt’s monopolistic Acthar revenue would be threatened if the government took action to limit the price paid for this drug by taxpayers. When the true details entered the market, the lawsuit claims that investors suffered damages. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 27, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1002.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected]. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm. Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com

Read more...
MNK Investors Deadline Reminder: Hagens Berman Reminds Mallinckrodt Investors of March 27, 2017 Lead Plaintiff Deadline and Alerts Them to the SEC Inquiry

SAN FRANCISCO, March 10, 2017 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP reminds investors in Mallinckrodt PLC (:MNK) of the March 27, 2017 Lead Plaintiff deadline and alerts them to the Company’s receipt of a subpoena from the SEC.
If you purchased or otherwise acquired securities of MNK between November 25, 2014 and January 18, 2017 and suffered over $50,000 in losses contact Hagens Berman Sobol Shapiro LLP.  For more information visit: https://www.hbsslaw.com/cases/MNK or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing [email protected]. Beginning in late 2014, MNK allegedly made assurances to investors that its drug, Acthar, produced sustainable revenues that were mostly attributable to sources other than Medicare and Medicaid. However, on November 16, 2016, a Citron Research report revealed that the percentage of Acthar 2014 and 2015 revenues attributable to Medicare alone was over 45% and 48%, respectively.  Citron also reported that the total percentage of Acthar 2014 and 2015 revenues attributable to both Medicare and Medicaid was over 60% and 61%, respectively.  This news drove the price of MNK shares down over 18%. In January 2017 the Company received a subpoena from the SEC for documents related to MNK’s public statements, filings and other disclosures regarding Acthar sales, profits, revenue, promotion and pricing. On January 18, 2017, the U.S. Federal Trade Commission announced that MNK would pay $100 million to settle charges that Acthar revenues were the product of an illegal monopoly.  This news drove the price of MNK down over 5%. “We’re evaluating management’s knowledge about revenue sources and omissions concerning when the FTC commenced its investigation into the unlawful practices and the subjects of the SEC’s inquiry,” said Hagens Berman partner Reed Kathrein. Whistleblowers: Persons with non-public information regarding MNK should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.  Under the new SEC whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.  For more information, call Reed Kathrein at 510-725-3000 or email [email protected].
About Hagens Berman
Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with offices in 10 cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the Firm and its successes can be found at www.hbsslaw.com. For the latest news visit our newsroom or follow us on Twitter at @classactionlaw.
Contact:
Reed Kathrein, 510-725-3000

Read more...
UPDATE - SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Mallinckrodt plc and Certain Officers – MNK

NEW YORK, March 07, 2017 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Mallinckrodt plc (“Mallinckrodt” or the “Company”) (:MNK) and certain of its officers.   The class action, filed in United States District Court, District of Columbia, is on behalf of a class consisting of investors who purchased or otherwise acquired Mallinckrodt securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934. If you are a shareholder who purchased Mallinckrodt securities between November 25, 2014 and January 18, 2017, both dates inclusive, you have until March 27, 2017 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.  [Click here to join this class action] Mallinckrodt is a public limited company organized in Ireland with its U.S. headquarters in St. Louis, Missouri.  Mallinckrodt develops and produces specialty pharmaceutical products, including generic drugs and imaging agents, and has in excess of $3.3 billion in annual revenue. On August 14, 2014, Mallinckrodt acquired Questcor Pharmaceuticals, Inc. (“Questcor”) in a $5.6 billion transaction. As a result of the acquisition, Mallinckrodt added HP Acthar Gel (“Acthar”), an injectable medication made from pigs’ pituitary glands, to its drug portfolio. Acthar is the only approved therapeutic preparation of adrenocorticotropic hormone (“ACTH”) in the U.S., and is approved by the U.S. Food and Drug Administration (“FDA”) as a treatment for 19 different conditions, including infantile spasms, and difficult-to-treat autoimmune and inflammatory conditions. In June 2013, Questcor had acquired the U.S. rights to market a synthetic ACTH drug, Synacthen Depot (“Synacthen”) from Novartis International AG. Although not stated at the time, Questcor’s acquisition of Synacthen was for the purpose of preventing its competitors from obtaining FDA approval for an alternative ACTH treatment, thereby maintaining its U.S. monopoly on ACTH treatments. The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.  Specifically, Defendants made false and misleading statements and failed to disclose material adverse facts about the long-term sustainability of the Company's monopolistic Acthar Gel ("Acthar") revenues and the dependence of the Company’s Acthar revenues on reimbursement by Medicare and Medicaid. On November 16, 2016, Citron Research published a report (the “Citron Report”) accusing Mallinckrodt and its Chief Executive Officer, Mark Trudeau, of downplaying the Company’s reliance on Medicare and Medicaid for Acthar revenue.  According to the Citron Report, a review of information published by the Centers for Medicare and Medicaid Services indicated that Medicare and Medicaid payments collectively amounted to 61.32% of Mallinckrodt’s Acthar revenues in 2015.  Following the Citron Report, Mallinckrodt’s share price fell $8.15, or 12.02%, to close at $59.65 on November 16, 2016.  On November 29, 2016, during a conference call, Trudeau advised investors “Acthar now represents a significantly greater proportion of our operating income than one-third.”  On this news, Mallinckrodt’s share price fell $5.25, or 9.1%, to close at $52.42 on November 29, 2016.  On January 18, 2017, the Federal Trade Commission (“FTC”) announced that Mallinckrodt had agreed to pay $100 million in connection with a joint settlement with the FTC and several states concerning charges that the Company’s efforts to stifle competing ACTH drugs had violated U.S. antitrust laws.  On news of the settlement, Mallinckrodt’s share price fell $2.89, or 5.85%, to close at $46.53 on January 18, 2017. The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]

Read more...
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Mallinckrodt plc and Certain Officers – MNK

NEW YORK, March 06, 2017 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Mallinckrodt plc (“Mallinckrodt” or the “Company”) (:MNK) and certain of its officers.   The class action, filed in United States District Court, District of Columbia, is on behalf of a class consisting of investors who purchased or otherwise acquired Caterpillar securities, seeking to recover compensable damages caused by defendants’ violations of the Securities Exchange Act of 1934. If you are a shareholder who purchased Mallinckrodt securities between November 25, 2014 and January 18, 2017, both dates inclusive, you have until March 27, 2017 to ask the Court to appoint you as Lead Plaintiff for the class.  A copy of the Complaint can be obtained at www.pomerantzlaw.com.   To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll free, ext. 9980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and number of shares purchased.  [Click here to join this class action] Mallinckrodt is a public limited company organized in Ireland with its U.S. headquarters in St. Louis, Missouri.  Mallinckrodt develops and produces specialty pharmaceutical products, including generic drugs and imaging agents, and has in excess of $3.3 billion in annual revenue. On August 14, 2014, Mallinckrodt acquired Questcor Pharmaceuticals, Inc. (“Questcor”) in a $5.6 billion transaction. As a result of the acquisition, Mallinckrodt added HP Acthar Gel (“Acthar”), an injectable medication made from pigs’ pituitary glands, to its drug portfolio. Acthar is the only approved therapeutic preparation of adrenocorticotropic hormone (“ACTH”) in the U.S., and is approved by the U.S. Food and Drug Administration (“FDA”) as a treatment for 19 different conditions, including infantile spasms, and difficult-to-treat autoimmune and inflammatory conditions. In June 2013, Questcor had acquired the U.S. rights to market a synthetic ACTH drug, Synacthen Depot (“Synacthen”) from Novartis International AG. Although not stated at the time, Questcor’s acquisition of Synacthen was for the purpose of preventing its competitors from obtaining FDA approval for an alternative ACTH treatment, thereby maintaining its U.S. monopoly on ACTH treatments. The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.  Specifically, Defendants made false and misleading statements and failed to disclose material adverse facts about the long-term sustainability of the Company's monopolistic Acthar Gel ("Acthar") revenues and the dependence of the Company’s Acthar revenues on reimbursement by Medicare and Medicaid. On November 16, 2016, Citron Research published a report (the “Citron Report”) accusing Mallinckrodt and its Chief Executive Officer, Mark Trudeau, of downplaying the Company’s reliance on Medicare and Medicaid for Acthar revenue.  According to the Citron Report, a review of information published by the Centers for Medicare and Medicaid Services indicated that Medicare and Medicaid payments collectively amounted to 61.32% of Mallinckrodt’s Acthar revenues in 2015.  Following the Citron Report, Mallinckrodt’s share price fell $8.15, or 12.02%, to close at $59.65 on November 16, 2016.  On November 29, 2016, during a conference call, Trudeau advised investors “Acthar now represents a significantly greater proportion of our operating income than one-third.”  On this news, Mallinckrodt’s share price fell $5.25, or 9.1%, to close at $52.42 on November 29, 2016.  On January 18, 2017, the Federal Trade Commission (“FTC”) announced that Mallinckrodt had agreed to pay $100 million in connection with a joint settlement with the FTC and several states concerning charges that the Company’s efforts to stifle competing ACTH drugs had violated U.S. antitrust laws.  On news of the settlement, Mallinckrodt’s share price fell $2.89, or 5.85%, to close at $46.53 on January 18, 2017. The Pomerantz Firm, with offices in New York, Chicago, Florida, and Los Angeles, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com
CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]

Read more...

Ratios

vs
industry
vs
history
PE Ratio 7.51
MNK's PE Ratio is ranked higher than
76% of the 556 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.48 vs. MNK: 7.51 )
Ranked among companies with meaningful PE Ratio only.
MNK' s PE Ratio Range Over the Past 10 Years
Min: 7.47  Med: 21.44 Max: 73.31
Current: 7.51
7.47
73.31
Forward PE Ratio 5.30
MNK's Forward PE Ratio is ranked higher than
93% of the 202 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.39 vs. MNK: 5.30 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 41.85
MNK's PE Ratio without NRI is ranked higher than
56% of the 544 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.85 vs. MNK: 41.85 )
Ranked among companies with meaningful PE Ratio without NRI only.
MNK' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.7  Med: 47.39 Max: 3311.75
Current: 41.85
12.7
3311.75
Price-to-Owner-Earnings 6.06
MNK's Price-to-Owner-Earnings is ranked higher than
93% of the 293 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.45 vs. MNK: 6.06 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MNK' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 6.03  Med: 8.14 Max: 9.93
Current: 6.06
6.03
9.93
PB Ratio 0.77
MNK's PB Ratio is ranked higher than
91% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. MNK: 0.77 )
Ranked among companies with meaningful PB Ratio only.
MNK' s PB Ratio Range Over the Past 10 Years
Min: 0.76  Med: 2.02 Max: 3.59
Current: 0.77
0.76
3.59
PS Ratio 1.33
MNK's PS Ratio is ranked higher than
74% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. MNK: 1.33 )
Ranked among companies with meaningful PS Ratio only.
MNK' s PS Ratio Range Over the Past 10 Years
Min: 1.11  Med: 2.39 Max: 6.35
Current: 1.33
1.11
6.35
Price-to-Free-Cash-Flow 8.19
MNK's Price-to-Free-Cash-Flow is ranked higher than
94% of the 226 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.83 vs. MNK: 8.19 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MNK' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.55  Med: 14.05 Max: 2749.62
Current: 8.19
5.55
2749.62
Price-to-Operating-Cash-Flow 5.81
MNK's Price-to-Operating-Cash-Flow is ranked higher than
93% of the 288 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.62 vs. MNK: 5.81 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MNK' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.7  Med: 13.84 Max: 45.78
Current: 5.81
4.7
45.78
EV-to-EBIT 64.71
MNK's EV-to-EBIT is ranked lower than
84% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. MNK: 64.71 )
Ranked among companies with meaningful EV-to-EBIT only.
MNK' s EV-to-EBIT Range Over the Past 10 Years
Min: 19.4  Med: 48.1 Max: 231
Current: 64.71
19.4
231
EV-to-EBITDA 9.91
MNK's EV-to-EBITDA is ranked higher than
79% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. MNK: 9.91 )
Ranked among companies with meaningful EV-to-EBITDA only.
MNK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 8.1  Med: 14.6 Max: 34.2
Current: 9.91
8.1
34.2
PEG Ratio 2.78
MNK's PEG Ratio is ranked higher than
54% of the 293 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.90 vs. MNK: 2.78 )
Ranked among companies with meaningful PEG Ratio only.
MNK' s PEG Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 3.26
Current: 2.78
0
3.26
Current Ratio 1.40
MNK's Current Ratio is ranked lower than
83% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. MNK: 1.40 )
Ranked among companies with meaningful Current Ratio only.
MNK' s Current Ratio Range Over the Past 10 Years
Min: 1.2  Med: 2.16 Max: 2.86
Current: 1.4
1.2
2.86
Quick Ratio 1.05
MNK's Quick Ratio is ranked lower than
81% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. MNK: 1.05 )
Ranked among companies with meaningful Quick Ratio only.
MNK' s Quick Ratio Range Over the Past 10 Years
Min: 0.93  Med: 1.59 Max: 2.41
Current: 1.05
0.93
2.41
Days Inventory 90.19
MNK's Days Inventory is ranked higher than
67% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.29 vs. MNK: 90.19 )
Ranked among companies with meaningful Days Inventory only.
MNK' s Days Inventory Range Over the Past 10 Years
Min: 71.49  Med: 81.23 Max: 169.11
Current: 90.19
71.49
169.11
Days Sales Outstanding 55.66
MNK's Days Sales Outstanding is ranked higher than
75% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. MNK: 55.66 )
Ranked among companies with meaningful Days Sales Outstanding only.
MNK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.29  Med: 73.29 Max: 105.41
Current: 55.66
50.29
105.41
Days Payable 29.24
MNK's Days Payable is ranked lower than
87% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.53 vs. MNK: 29.24 )
Ranked among companies with meaningful Days Payable only.
MNK' s Days Payable Range Over the Past 10 Years
Min: 26.34  Med: 41.19 Max: 52.77
Current: 29.24
26.34
52.77

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -22.90
MNK's 3-Year Average Share Buyback Ratio is ranked lower than
83% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. MNK: -22.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MNK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -26.3  Med: -26.2 Max: -22.9
Current: -22.9
-26.3
-22.9

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.56
MNK's Price-to-Median-PS-Value is ranked higher than
88% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. MNK: 0.56 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MNK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.5  Med: 0.98 Max: 2.48
Current: 0.56
0.5
2.48
Earnings Yield (Greenblatt) % 1.54
MNK's Earnings Yield (Greenblatt) % is ranked lower than
59% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. MNK: 1.54 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MNK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.4  Med: 2.1 Max: 5.1
Current: 1.54
0.4
5.1

More Statistics

Revenue (TTM) (Mil) $3,189
EPS (TTM) $ 5.29
Beta1.74
Short Percentage of Float16.69%
52-Week Range $38.97 - 85.83
Shares Outstanding (Mil)99.35

Analyst Estimate

Sep17 Sep18 Sep19
Revenue (Mil $) 3,311 3,379 3,452
EPS ($) 7.49 8.44 9.28
EPS without NRI ($) 7.49 8.44 9.28
EPS Growth Rate
(Future 3Y To 5Y Estimate)
4.00%
Dividends per Share ($)
» More Articles for MNK

Headlines

Articles On GuruFocus.com
InvestorsObserver releases covered-call reports for Archer-Daniels-Midland, Bunge, Lowes, Mallinckro May 24 2017 
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin May 23 2017 
Mallinckrodt To Present At Goldman Sachs 38th Annual Global Healthcare Conference May 12 2017 
First Patient Enrolled in Mallinckrodt Phase 2 Trial of StrataGraft® Regenerative Skin Tissue May 04 2017 
Mallinckrodt Celebrates 30th Anniversary of THERAKOS® Photopheresis Therapy May 03 2017 
Mallinckrodt Data from New Company-Sponsored Studies Presented at American Academy of Neurology 69th Apr 28 2017 
Mallinckrodt To Present At UBS Global Healthcare Conference Apr 24 2017 
Mallinckrodt To Present At Deutsche Bank 42nd Annual Healthcare Conference Apr 05 2017 
MNK DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Mallinck Mar 24 2017 
DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Mallin Mar 23 2017 

More From Other Websites
First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar® Gel (Repository Corticotropin... May 23 2017
Mallinckrodt & Express Scripts: What Chanos Got Wrong May 22 2017
Top hedge fund managers shared these 5 trade ideas at the SALT Conference May 20 2017
Short-seller criticizes 'murky alliance' between Mallinckrodt, Express Scripts May 19 2017
Jim Chanos has a way to profit on the drug overpricing backlash and still hates Tesla May 19 2017
[$$] Jim Chanos Predicts Stock Drop for Mallinckrodt May 18 2017
Jim Chanos is shorting 2 drug stocks with a 'murky alliance' May 18 2017
Chanos on Mallinckrodt, Express Scripts, Tesla and China May 18 2017
Two More Stock Picks From Hedge Fund Leaders at SALT May 18 2017
Why Chanos Is Shorting Mallinckrodt and Express Scripts May 18 2017
Edited Transcript of MNK earnings conference call or presentation 8-May-17 12:30pm GMT May 12 2017
Mallinckrodt To Present At Goldman Sachs 38th Annual Global Healthcare Conference May 12 2017
Mallinckrodt Plc – Value Analysis (NYSE:MNK) : May 9, 2017 May 09 2017
Mallinckrodt Earnings, Revenues Beat Estimates in Q1 May 08 2017
Mallinckrodt (MNK) Tops Q1 Earnings, Sales May 08 2017
Mallinckrodt's stock jumps after profit and sales beat May 08 2017
Mallinckrodt Plc breached its 50 day moving average in a Bullish Manner : MNK-US : May 8, 2017 May 08 2017
Mallinckrodt tops Street 1Q forecasts May 08 2017
Mallinckrodt plc Reports Earnings Results for First Quarter of Fiscal 2017 May 08 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat